• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Astri Therapeutics Inc (NQ: ATXS )

    12.36 +0.06 (+0.49%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 219,205
    Open 12.40
    Bid (Size) 10.53 (1)
    Ask (Size) 12.68 (1)
    Prev. Close 12.30
    Today's Range 12.10 - 12.63
    52wk Range 4.260 - 16.90
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    ATXS Stock Earnings: Astria Therapeutics Misses EPS for Q2 2024
    ATXS stock results show that Astria Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
    From Astria Therapeutics, Inc.
    Via Business Wire

    Performance

    YTD
    +58.66%
    +58.66%
    1 Month
    +6.37%
    +6.37%
    3 Month
    +36.57%
    +36.57%
    6 Month
    -12.40%
    -12.40%
    1 Year
    +41.26%
    +41.26%

    More News

    Read More
    Astria Therapeutics Chooses Ypsomed’s YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema
    From Astria Therapeutics, Inc.
    Via Business Wire
    Astria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare Conference
    From Astria Therapeutics, Inc.
    Via Business Wire
    Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Astria Therapeutics, Inc.
    Via Business Wire
    Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Astria Therapeutics
    Via Business Wire
    Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Astria Therapeutics, Inc.
    Via Business Wire
    Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
    From Astria Therapeutics, Inc.
    Via Business Wire
    Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
    From Astria Therapeutics, Inc.
    Via Business Wire
    Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress
    From Astria Therapeutics, Inc.
    Via Business Wire
    ATXS Stock Earnings: Astria Therapeutics Misses EPS for Q1 2024
    Via InvestorPlace
    Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
    From Astria Therapeutics, Inc.
    Via Business Wire
    Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting
    From Astria Therapeutics, Inc.
    Via Business Wire
    Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Astria Therapeutics, Inc.
    Via Business Wire
    Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors
    From Astria Therapeutics, Inc.
    Via Business Wire
    Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Astria Therapeutics, Inc.
    Via Business Wire
    Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
    From Astria Therapeutics, Inc.
    Via Business Wire
    Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Astria Therapeutics, Inc.
    Via Business Wire
    ATXS Stock Earnings: Astria Therapeutics Misses EPS for Q4 2023
    Via InvestorPlace
    Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
    From Astria Therapeutics, Inc.
    Via Business Wire
    Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting
    From Astria Therapeutics, Inc.
    Via Business Wire
    Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference
    From Astria Therapeutics, Inc.
    Via Business Wire
    Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Astria Therapeutics, Inc.
    Via Business Wire
    Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering
    From Astria Therapeutics, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.